Jared Whitlock


Email: jwhitlock@sdbj.com
Phone: 858-634-4636 Extension: 3130

Recent Stories

Look Ahead: Dexcom Plots Strategy for Competitive and Innovative Sector

For Dexcom Inc., September brought unwelcome news. As one analyst put it, “The phantom that has been chasing Dexcom has materialized.”

Tease photo

Tandem Diabetes Care Increases S.D. Manufacturing Space

The company’s new 50,000-square-foot facility on Barnes Canyon Road recently became fully operational.

Cannabis-Derived Drug Granted Priority Review

Greenwich Biosciences developed epidolex, a treatment for seizures in two rare, severe childhood-onset epilepsy disorders.

Preparing For Pot

ECONOMY: From Land to Law to Labs, Marijuana Sales Bring Changes, Opportunities

Inside a 1,000-square-foot room, yellow incandescent light filters down on leafy green marijuana plants in neat rows. Soon, plants and lighting will be added vertically — like a double-decker bus — so operator Outco can increase production more than twofold.

Tease photo

Organovo’s 3D Bioprinted Tissue Treatment Receives Orphan Drug Designation

Organovo designs and creates functional, three-dimensional human tissues for use in drug discovery, clinical development and therapeutic applications.

Palomar Nurses, Caregivers Ratify Contract

HEALTH: Four-Year Deal Brings Retroactive Pay Increases

Both nurse and caregiver unions at Palomar Health recently voted to approve four-year deals with management after seven months of working without a contract.

2017 Newsmakers: Win, Lose or Draw, Ionis Shows It Is a Top Competitor

2017 Newsmakers

In 2017, Carlsbad’s Ionis Pharmaceuticals basked in the success of a drug it developed to treat spinal muscular atrophy in infants.

Tease photo

2017 Newsmakers: Tocagen Advances Cancer Fight with IPO, Breakthrough Designation

2017 Newsmakers

Tocagen brought on Martin “Marty” Duvall as CEO more than a year ago to commercialize its anti-cancer therapies. In 2017, the company marked several milestones on that front.

Tease photo

2017 Newsmakers: Hemker Exits After Huge Changes at Palomar Health

2017 Newsmakers

Robert Hemker, long an architect of Palomar Health District’s financial plans, retired in November.

Tease photo

Palomar Health Nurses, Caregivers Ratify 4-Year Contracts

Under the agreements, 3,000 employees received a retroactive pay raise.

2017 Newsmakers: Sempra Leader So Far Plays Right Cards in Texas

2017 Newsmakers

Besting Warren Buffett is a tall order. Under CEO Debra Reed, Sempra did just that.

Tease photo

Nobel Laureate to Retire From Salk Institute

Pioneering molecular biologist, Elizabeth Blackburn was named Salk’s president in November 2015.

Ionis and Biogen Expand Partnership

Carlsbad’s Ionis Pharmaceuticals and Biogen have expanded their collaboration to identify new drug candidates for the treatment of spinal muscular atrophy (SMA).

New Owner Brings New Strategy for Proton Therapy Center

MEDICINE: It Will Seek Closer Ties With UCSD Health, Bolster Marketing

The region’s first and only proton therapy center has relaunched under new ownership and management after a chapter 11 bankruptcy filing protection last spring.

Tease photo

Sirenas LLC Lands Second Bill & Melinda Gates Foundation Grant

The marine-centric biotech, which has now secured $1.68 million, will use the money to discover potential therapies to treat infectious diseases.

Palomar Health Reaches Tentative Deals with Nurses, Caregivers

The agreements, which cover more than 3,000 employees who are seven months into working without a contract, must still be ratified.

Bridgepoint Is on Both Defense and Offense

EDUCATION: School Faces Lawsuit, Changes Marketing

In 2010, for-profit Bridgepoint Education moved to a prominent downtown San Diego high-rise. Its name and logo affixed outside the top floors of 600 B Street symbolized the company’s rapid rise.

Tease photo

Genoptix to Buy Rosetta Genomics for $10M

The deal, expected to close during the first quarter of 2018, was unanimously approved by both companies’ boards.

Executive Q&A Rakesh Patel, Neighborhood Healthcare

In 2002, Rakesh Patel started as a family physician at Neighborhood Healthcare, an organization he now leads.

Tease photo

Renova Therapeutics’ Drug Receives FDA Fast Track Status

The lead product candidate is a gene transfer drug to treat heart disease.

Becoming Part of The (Health) Plan

Wellness Cos. Help Care and Coverage Providers Find Ways to Effectively Reach and Influence Diverse Customer Bases

Swaying rural teens in Arkansas to stay away from chewing tobacco, a habit ingrained in the local culture, is no easy task. Nor is crafting relatable messages for teens on the dangers of prescription painkiller abuse.

Tease photo

Stakeholder Groups Endorse Sempra’s Purchase of Oncor

By April the Public Utility Commission of Texas will decide whether to OK Sempra buying Energy Future Holdings, which owns 80 percent of Oncor.

Tease photo

In Budget Move, Scripps Health to Cut Corporate Services By $30M

HEALTH: It Will Also Restructure Top Hospital Leadership

Scripps Health will cut corporate services by $30 million and replace the chief executive role at its hospitals with a new leadership model, according to media reports.

Tease photo

FERC Approves Sempra’s Oncor Bid

Sempra Energy’s $9.45 billion plan to obtain an ownership interest in Texas energy giant Oncor Electric took another step forward on Dec. 12.

Tease photo

Dart Neuroscience Laying Off 265 Employees, Shuttering Operations

The cessation will take effect Feb. 9.

Athena Names Holly Smithson as CEO

Smithson previously was the vice president of business strategy at the California Life Sciences Association.

Ionis Earns $45M Licensing Fee for Huntington’s Disease Drug

The Carlsbad drugmaker has licensed what’s being called a groundbreaking treatment following promising early trial results.

Halozyme Licensing Deal Could Be Worth Much More Than $40M

San Diego’s Halozyme Therapeutics will receive a $40 million upfront payment, and potentially much more, as part of a collaboration and licensing deal with Alexion Pharmaceuticals.

Metacrine Gets $22 Million in Funding Round, New Board Member

San Diego biotech Metacrine, which is working on drugs for liver and metabolic diseases, has closed a $22 million Series B financing round.

Metacrine Gets $22M in Funding Round, New Board Member

San Diego biotech Metacrine, which is working on drugs for liver and metabolic diseases, has closed a $22 million Series B financing round.

Proton Therapy Center Relaunches with New Ownership

California Protons is one of only two proton therapy centers in California and 25 nationwide.

Three S.D. Scientists Receive Breakthrough Prize

Three high-profile scientists took home the prize billed as the Oscars of Science.

NanoCellect Raises $10M in Funding Round

San Diego biotech raised $10 million in a Series B round, led by investment from Illumina Ventures.

Tease photo

Section 32 Adds A Key Player to its Roster

The venture capital firm in San Diego that was launched earlier this year by former Google Ventures CEO Bill Maris has added a big name in health care.

Adamis Applying for Approval of Product that Treats Opioid Overdose

the pharmaceuticals company has submitted an application to the U.S. Food and Drug Administration seeking to begin human testing of a drug and product combo for treating opioid overdoses.

Investors Win Class-Action Status in SeaWorld Lawsuit

Investors who sued SeaWorld Entertainment for misleading on the impact of the documentary “Blackfish” have been granted class-action status.

State Attorney General Files a Lawsuit Against Bridgepoint Education

California is suing for-profit Ashford University and its parent company, San Diego-based Bridgepoint Education, alleging false promises to persuade students to enroll in the online school.

Odonate’s Planned IPO Aims for $150 Million Mark

Odonate Therapeutics has stated terms for its eye-popping $150 million initial public offering, the latest from the stealth IPO that emerged in mid-November.

CRO Navigates Tough Preclinical Testing Stage for Cos.

BIOTECH: Challenges Are Big And Small in Testing on Animals

Explora Biolabs is part of San Diego’s biotech cluster. But CEO Richard Lin likens the company to a hotel.

Tease photo

S.D. Set for a Big Role as Biotech Irras Maps Out Strategy

BIOTECH: S.D. Could Be Headquarters; Co. Lists First in Europe

What does Sweden’s stock market have to do with San Diego? Look no further than the company Irras Ab.

Tease photo

Sommetrics Adds to Board of Directors, Advisory Board

Sommetrics has added Raymond Huggenberger to its board of directors and Randall Whitfield to its advisory board.

CPUC Turns Down San Diego Gas & Electric's 2007 Wildfires Request

The CPUC denied a San Diego Gas & Electric request to bill ratepayers $379 million in damages related to the 2007 wildfires.

Economic Index: S.D. Economy Rises on National Outlook

A local index of leading economic indicators in San Diego County was up 0.6 percent in October.

NanoCellect Raises $10M in Funding Round

San Diego biotech NanoCellect Biomedical raised $10 million in a Series B round, led by investment from Illumina Ventures.

Dexcom Partners with Eli Lilly

A newly formed partnership calls for the integration of Dexcom’s continuous glucose monitoring (CGM) system with Eli Lilly and Company’s insulin delivery platform.

Synthorx Appoints Laura Shawver as CEO

Laura Shawver, who has a background as an entrepreneur and drug developer, has been tapped.

‘Genomics Evangelist’ Envisions Group Effort

Dawn Barry is a self-described genomics evangelist. But she’s not preaching to the choir.

Tease photo

New Ionis COO Named

Brett Monia, a founding member of Ionis Pharmaceuticals, has been named the company’s COO.

San Diego County Got Big Boost in Life Science Jobs in 2016

FINANCE: Report Finds VC Investment Down; Average Wages Fell

Employment in the life sciences sector in San Diego County shot up nearly 19 percent year over year, according to a recent industry report for the state.

Tease photo

‘Fully Commercialized,’ Biocept Ready for Big Role

BIOTECH: Co.’s Biopsies Enable Targeted Therapy

Tissue biopsies have long been the standard in cancer care. Yet sometimes the tissue-removal procedure can’t be done for medical reasons.

Tease photo